sorafenib

Pfizer's study found so-called "progression-free survival," the period of time that a patient's tumors don't grow and the disease didn't worsen, was 6.7 months on average in the group taking its drug, versus 4.7 months in the group taking Nexavar, also known as sorafenib.

Pfizer Kidney Drug Gains FDA Approval Joan E. Solsman 2012

Axitinib showed only a two-month advantage over an existing drug called sorafenib, from Bayer AG and Onyx Pharmaceuticals .

Pfizer Kidney Cancer Drug Gets FDA Panel's Nod Thomas M. Burton 2011

Nexavar, which is also known as sorafenib, was compared in the study with a placebo in combination with chemotherapy.

Bayer Cancer Drug Fails to Meet Primary Goal 2010

Nexavar, also known by the generic name sorafenib, is made by Bayer and

U.K. Rejects Appeal on Bayer Cancer Drug 2010

Nexavar, also known as sorafenib, is a Bayer AG drug, while Sutent, also known as sunitinib, is sold by Pfizer Inc.

Novartis Kidney Cancer Treatment 2008

He said the first patient has been enrolled in a Phase 2b study comparing JX-594 with standard care in 120 liver cancer patients who have stopped responding to Nexavar, also known as sorafenib, sold by Onyx Pharmaceuticals.

Reuters: Press Release 2011

Regorafenib is similar to Bayer's Nexavar drug, scientifically known as sorafenib, and both drugs are so-called multikinase inhibitors that quell cancer cell growth and prevent new blood vessels that could feed tumors.

Reuters: Press Release 2011

Since this protein is one of most important members involved in the RAF/MEK/ERK signaling pathway, MAPK14 is associated with sorafenib, which is a drug used for the treatment of advanced renal cell carcinoma (primary kidney cancer) and advanced hepatocellular carcinoma

PLoS ONE Alerts: New Articles Gang Wu et al. 2010

Bayer argued that Cipla's generic sorafenib, which is branded as Soranib, if examined and granted marketing rights, will be seen as a spurious drug as per the Drugs and Cosmetics Act. The Delhi High Court on a judgment delivered on 18th of August last year, dismissed the writ petition filed by Bayer Corporation and asked the company to pay costs amounting to Rs

DWS Full News Feed pillscribe 2010

Bayer argued that Cipla's generic sorafenib, which is branded as Soranib, if examined and granted marketing rights, will be seen as a spurious drug as per the Drugs and Cosmetics Act. The Delhi High Court on a judgment delivered on 18th of August last year, dismissed the writ petition filed by Bayer Corporation and asked the company to pay costs amounting to Rs

DWS Full News Feed 2010